Nektar Therapeutics
NKTR
$0.8968
$0.08149.98%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 24.12M | 23.49M | 21.64M | 23.89M | 24.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.12M | 23.49M | 21.64M | 23.89M | 24.14M |
| Cost of Revenue | 4.44M | 9.74M | 8.53M | 7.28M | 12.43M |
| Gross Profit | 19.69M | 13.75M | 13.11M | 16.60M | 11.71M |
| SG&A Expenses | 18.96M | 20.51M | 20.15M | 17.32M | 21.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.42M | 59.97M | 56.09M | 54.55M | 57.65M |
| Operating Income | -34.30M | -36.49M | -34.45M | -30.66M | -33.50M |
| Income Before Tax | -37.05M | -52.32M | -36.84M | -42.11M | -45.90M |
| Income Tax Expenses | 9.00K | 46.00K | -35.00K | -29.00K | -61.00K |
| Earnings from Continuing Operations | -37.06M | -52.36M | -36.80M | -42.08M | -45.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.06M | -52.36M | -36.80M | -42.08M | -45.84M |
| EBIT | -34.30M | -36.49M | -34.45M | -30.66M | -33.50M |
| EBITDA | -33.31M | -35.03M | -32.85M | -29.01M | -31.81M |
| EPS Basic | -0.18 | -0.25 | -0.19 | -0.22 | -0.24 |
| Normalized Basic EPS | -0.11 | -0.12 | -0.12 | -0.11 | -0.11 |
| EPS Diluted | -0.18 | -0.25 | -0.19 | -0.22 | -0.24 |
| Normalized Diluted EPS | -0.11 | -0.12 | -0.12 | -0.11 | -0.11 |
| Average Basic Shares Outstanding | 209.25M | 208.83M | 194.75M | 191.04M | 190.41M |
| Average Diluted Shares Outstanding | 209.25M | 208.83M | 194.75M | 191.04M | 190.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
